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Simple Summary: Since the beginning of COVID-19 pandemic, no specific drugs have been 
available to treat the SARS-CoV-2 infection, therefore antibiotics have been often used both for 
prophylactic and therapeutic purposes. Their wide use, though, is known to contribute to the 
emergence of antimicrobial resistance. Aiming at evaluating the impact of the COVID-19 pandemic 
on the distribution and characteristics of bacterial infections, and on the frequency of antimicrobial 
resistance, we investigated the microbial strains identified through laboratory tests on clinical 
specimens from COVID-19 and non-COVID-19 patients accessing an Italian tertiary hospital over 
nearly one year. We highlighted that COVID+ patients bore a significantly higher number of 
bacterial species. Eight out of the 100 species identified were isolated exclusively from COVID+ and 
most of them are known to establish infections only in immunocompromised patients. Resistance 
to every tested antibiotic was seen in 8.3% of the isolates with a correlation with the positivity to 
COVID, but neither all COVID+ or COVID− isolates showed characteristic responses to the tested 
antibiotics. The predicted increase of antibiotic resistance is not observable yet, but the higher 
frequency of multi-resistant COVID+ isolates suggests that it is actually occurring, further calling 
for the definition of alternative treatments of COVID-19 infections. 
Abstract: The global onset of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus 
infections happened suddenly, hence imposing a rapid definition of effective therapeutic 
approaches. Antibiotics were included among the prophylactic agents because of both the similarity 
between SARS-CoV-2 and atypical pneumonia symptoms, and the immune-modulating and anti-
inflammatory properties of such drugs. Although, this approach could exacerbate the emergence of 
antimicrobial resistance. To evaluate the impact of the COVID-19 pandemic on the spread and 
characteristics of bacterial infections, as well as on the frequency of antimicrobial resistance, we 
investigated and compared clinical bacterial strains isolated in an Italian hospital from COVID-19 
patients and non-COVID-19 patients during and before the COVID-19 outbreak. Data clearly 
indicate the impact of the COVID-19 pandemic on bacterial infections: not only some bacterial 
species were found in either COVID-19 positive or in COVID-19 negative patients, but isolates from 
COVID-19 patients also showed higher levels of antimicrobial resistance. Nevertheless, despite 
some bacterial species were isolated only before or over the pandemic, no differences were observed 
among the antimicrobial resistance levels. Overall, these results recapitulate the current situation of 
microbial infections and could also provide an overview of the impact of COVID-19 on bacterial 
pathogens spread and resistance. 
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The sudden, massive, and rapid spread of the pandemic caused by the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) virus (COVID-19) has demanded the 
adoption of drastic actions to contain the further spread of the infection and to rapidly 
adjust healthcare systems and frameworks. In Italy, where the first domestic case was 
detected on 28 February 2020, early epidemic phases caught the National Healthcare 
System unprepared for such an event and a severe health crisis was averted by a rigid 
lockdown from 9 March to 3 May 2020, followed by a period of mitigation. Unfortunately, 
new restrictive measures had to be reintroduced in November 2020 due to the increase in 
the number of cases [1]. In the first wave (from 21 February 2020 to 11 June 2020), the total 
number of diagnosed cases was 233,019 and the total number of deaths was 34,260, while 
in the shorter period of the second wave (from 14 September 2020 to 31 December 2020) 
409,241 cases were diagnosed and 38,535 people died. Southern Italian regions, which 
were preserved by the first wave, were the most affected during the second one [2]. 
Considering the urgency to alleviate the symptoms and resolve the infection, treatments 
are being experimentally defined [3]. The symptoms of COVID-19 infection are highly 
similar to atypical bacterial pneumonia [4–6] and this lead to the empirical decision to 
administer antimicrobials commonly used for the treatment of bacterial/fungal 
pneumonia in 72% of cases, worldwide, either to prevent the onset of concurrent 
infections or to exacerbate already present concomitant bacterial or fungal infections, 
despite microbial co-infections being observed only in 8% of COVID-infected patients [7]. 
Furthermore, antibiotics could be useful in the treatment of COVID-19 positive patients 
because of their immune-modulating, anti-inflammatory, and potential antiviral 
properties [8] has to be considered, however, the antiviral effectiveness of some antibiotics 
(aminoglycosides and meropenem) [9,10] has not been proven yet or has been proven to 
be limited (fluoroquinolones) [11]. 
As a consequence, despite the indications of scientific societies and working groups, 
antibiotics were over-prescribed and administered, particularly during the first wave of 
the pandemic in Italy. Early indications provided by scientific societies and working 
groups suggesting to limit the administration of targeted antibiotics only in the presence 
of a reasonable suspicion of concomitant bacterial or viral infection [12] were later 
confirmed by SIMIT (Italian Society of Infectious and Tropical Diseases) (November 2020) 
[13] and SIMG (Italian society of general medicine) (April 2021) [14]. 
In addition to the clinical oculate decision of prescribing antibiotics for the treatment 
of COVID-19 infections, an online survey carried out in the UK at the height of the initial 
outbreak has revealed that almost 20% of participants deliberately decided to take 
antibiotics as a preventive measure against COVID-19 infections [15]. 
Together, these factors may contribute to further exacerbating the emergence of 
antimicrobial resistance [16–18], and the World Health Organization (WHO), to prevent 
this, issued guidance to discourage antibiotic therapy or prophylaxis for patients with 
mild or moderate COVID-19 symptoms unless there is a clinical indication of a bacterial 
infection [19]. 
Aiming at evaluating the impact of the COVID-19 pandemic on the distribution and 
characteristics of bacterial infections, as well as on the frequency of antimicrobial 
resistance, we investigated and compared the characteristics of microbial strains 
identified through laboratory tests on clinical specimens from COVID-19 patients and 
non-COVID-19 patients. 
2. Materials and Methods 
2.1. Isolation of Strains 
The information on the isolates collected in the period between 26 March 2020 and 9 
January 2021 and analyzed over this study was collected at the San Luigi Hospital in Turin 
(Italy) (Supplementary Table S1). The sources of isolation were: articular liquid, ascites, 
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aspirated bronchus, bile, biopsy from lymph node, biopsy from other body sites, blood, 
bronchial lavage, catheter, catheter urine, cavitary liquid, cutaneous lesion, drainage 
liquid, exudate, feces, liquor, nasal tampon, oral tampon, peritoneal liquid, pharynx, 
bedsore, pleura liquid, prostatic material, pus, rectal tampon, sputum, surgical wound, 
ureter, urethra secretion, urine, vaginal secretion, venous catheter, and “others” (not 
specified in the medical report). For statistical reasons we grouped the clinical wards 
according to the corresponding clinical area: cardiology, ER, ICU (anesthesiology and 
reanimation), medicine (diabetology, geriatrics, internal medicine, hematology, low 
intensity COVID, medicine and surgery, neurology, oncology, pneumology, 
rehabilitation), surgery (general surgery, orthopedics, otolaryngology, thoracic surgery, 
urology) (Supplementary Table S1). Neither clinical nor demographic data were collected 
for patients from which the strains were isolated. Hence, Ethical Committee approval is 
not required. Bacteria isolation was carried out by seeding the samples onto selective 
media (VACUTEST KIMA and BIOMERIEUX ITALIA). Bacteria were identified at the 
genus or species level through the biochemical BD Phoenix™ (Becton Dickinson, Milan, 
Italy) system, which is based on 45 biochemical reactions whose outcomes, taken together, 
allow the identification of the microorganism. 
2.2. Antimicrobial Testing 
To establish the susceptibility of the bacterial isolates under investigation to the most 
commonly administered antibiotics, the antibiogram was obtained for each isolate 
according to the ISO and EUCAST Broth microdilution method. Briefly, the antibiogram 
was performed by inoculating 5 × 105 CFU/mL bacterial cells in MH-F broth (Mueller 
Hinton broth supplemented with 5% lysed horse blood and 20 mg/L β-NAD), 
supplemented with antibiotic in multi-well plates and incubated at 35 °C for between 16 
and 48 h (depending on the species), after which plates were visually inspected to 
determine the MIC (minimum inhibitory concentration) of the antibiotic against the tested 
microorganism. The tested concentrations of each antibiotic were chosen to include at 
least twice the highest clinical breakpoint concentration and half of the lowest breakpoint 
concentration. For each species, a different set of antibiotics was tested, as reported in 
Supplementary Table S2. Each isolate was scored as R (Resistant), I (Intermediate), or S 
(Susceptible) to each tested antibiotic according to the clinical breakpoints defined by 
EUCAST for the corresponding species and antibiotics and reported in the clinical 
breakpoint table v7.0 [20]. 
2.3. Statistical Analyses 
Provided that we did not have access to clinical and demographic data of the patients 
from which the strains were isolated, the relevance of such variables on the statistical 
analyses cannot be assessed. For alpha and beta diversities estimation and comparison, 
isolates were grouped as being isolated on the same date (month and year), from the same 
specimen, and from patients with the same COVID-19 status (infected or not). With this 
grouping method, isolates from the same patient would be likely pooled together (hence 
erroneously considered independent). To assess whether this grouping led to biased 
results, all the statistical tests described afterwards have been carried out also on samples 
grouped by patient, obtaining the same results as those obtained on the samples grouped 
as previously described. Hence, the pooling of isolates did have a minor impact, if any, on 
the analyses. Alpha (within-sample richness,) and beta-diversity (between-sample 
dissimilarity) estimates were computed using the phyloseq R package [21]. Briefly, 
whereas alpha diversity indexes (observed, Shannon, or Simpson) summarize the 
structure of an ecological community (in this case a group of isolates) with respect to its 
richness (in this case the number of species), evenness (distribution of abundances of the 
species), or both, beta diversity is the difference in diversity of species between two or 
more group of isolates, expressed as the total number of species that are shared or unique 
to each of the groups being compared [22]. Principal coordinate analysis was carried out 
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by using the function ordinate() in the phyloseq library [21] on Jaccard distances calculated 
on the composition of microbial communities in groups of isolates (composed as 
described earlier). To assess the differences among groups, permutational multivariate 
analysis of variance (permanova) was performed using the adonis() function of the vegan 
R package with 999 permutations [23]. Two-sided, unpaired Welch t-statistics were com-
puted using the function mt() in the phyloseq library [21], and the p-values were adjusted 
for multiple comparisons controlling the family-wise Type I error rate (minP procedure) 
[24]. Unpaired two-samples Mann–Whitney U test (Wilcoxon test) statistics were com-
puted using the function wilcox.test() in the stats library [25] and the p-values were ad-
justed for multiple comparisons by computing false discovery rate (FDR)-adjusted p-val-
ues using the Benjamini–Hochberg procedure [26]. For each tested antibiotic, resistance 
percentage was calculated as the number of resistant isolates over the total isolates tested 
with the corresponding antibiotic. Fisher exact test was carried out to assess the enrich-
ment of any isolation sources among the isolates from COVID+ and COVID− patients 
showing significantly different levels of susceptibilities to the tested antibiotics. To evalu-
ate the impact of different typology of COVID-19 cases and therapeutic approaches on the 
insurgence of (resistant) bacterial infections, alpha and beta diversities, as well as the bac-
terial species were compared between samples isolated over the first and the second pan-
demic Italian waves, which lasted from March to September 2020 and from October 2020 
to January 2021 respectively. 
All figures were created using R. All diagrams were created using R and combined 
as panels with the Inkscape software. 
3. Results 
3.1. Isolation of Bacterial Strains from Clinical Specimens Collected from COVID+ and COVID− 
Patients 
In a period of almost one year (between March 2020 and January 2021), a total of 2002 
bacterial strains were isolated from 1090 patients symptomatic of bacterial infections, 
identified, and characterized at the San Luigi Hospital in Turin (Italy) (Supplementary 
Table S1). Among these isolates, 28.97% (n = 580) were isolated from 252 patients (23.1% 
of all the analyzed patients) having been tested positive for COVID-19 at the time of sam-
ples collection (COVID+), the remaining 1422 strains (76.9%) were isolated from 838 
COVID-19 negative (COVID−) patients (Figure 1a). Notably, the number of bacterial 
strains isolated per month from COVID+ patients did correlate with the number of new 
COVID-19 patients observed at the national level [27] (Pearson r = 0.96, p = 4.62*10^-06, 
Figure 1b). Contrarily, the number of bacterial strains isolated per month from COVID− 
patients did not correlate with the number of new COVID-19 patients (Pearson r = −0.41, 
p = 0.214) nor with the number of bacterial strains isolated from COVID+ patients (Pearson 
r = −0.26, p = 0.436) (Figure 1b). Despite the number of patients from which strains were 
isolated was greater over the first time-periods than over the second time-periods (respec-
tively 648 and 478, with 36 patients being included in both groups), the average number 
of patients analyzed per month was greater over the second time-periods (119.5 vs. 92.57 
average patients per month over the first period). Furthermore, whereas only the 10.4% 
of the patients analyzed over the first period were COVID+, the 41.2% of patients analyzed 
over the second period were COVID+, in line with the peak of new COVID-19 cases ob-
served at the national level over the second period (with a peak of 40,902 new cases on the 
13 of November 2020) compared to the first period (with a peak of 6203 new cases on the 
26 of March 2020). The analysis of specimens from 406 patients resulted in the isolation of 
multiple isolates belonging to different species. Conversely, the microbiological analysis 
on the remaining 684 patients resulted in the isolation of a single strain. The COVID-19 
status of the patient (having been tested positive or negative for COVID) and the isolation 
of multiple or single strains from the analyzed specimen were not independent (Chi-
square test, Χ2(1, N = 1090) = 7.3, p = 0.007). In particular, 64.9% and 55.5% of specimens 
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from COVID-19 negative and positive patients respectively resulted in the isolation of a 
single strain (Supplementary Figure S1). The 44.5% of COVID+ patients provide multiple 
isolates, which, compared to the 35.1% of COVID− patients resulting in the isolation of 
multiple strains, indicated that COVID+ patients had a higher prevalence of multiple 
strains. Our dataset included patients hospitalized in five different clinical areas: cardiol-
ogy, ER (Emergency Room), ICU (Intensive Care Unit), medicine, and surgery (Figure 1c). 
Some patients were hospitalized in multiple clinical areas (Supplementary Figure S2a). 
Medicine was the clinical area where almost half of the patients accessed (n = 505 out of 
1090 patients, 46.3%), followed by the ER (n = 330, 30.3%), the ICU (n = 142, 13.0%), surgery 
(n = 111, 10.6%), and cardiology (n = 41, 3.8%) (Figure 1c). Notably, the same order was 
not confirmed when considering the number of isolates: whereas medicine was again the 
clinical area from which the highest number of strains were isolated (n = 795, 44.5%), the 
second and third place were switched, with ICU providing the second-highest number of 
isolates (n = 559, 27.9%), and the ER being the third (n = 422, 21.2%) (Figure 1c). In fact, the 
number of patients hospitalized in the different clinical areas did not correlate with the 
number of strains isolated from patients hospitalized in the corresponding clinical area 
(Pearson p = 0.083). It is worth noting that, whereas the average number of isolates per 
patient hospitalized in cardiology, in the ER, in medicine, and in surgery ranged between 
1.2 and 1.5 (respectively: 1.2, 1.3, 1.5, 1.5), the specimens collected from patients hospital-
ized in the ICU provided a higher average of isolates (3.9). The same trend was observed 
when considering the entire set of isolates and when considering separately the isolates 
from COVID+ or COVID− patients: the average number of isolates per patient was ap-
proximately 2 for both subsets of samples (Supplementary Figure S2b,c). 
A significant relationship was found between the number of COVID+ and COVID− 
patients in different clinical areas and the number of isolates per clinical area (Chi-square 
test, Χ2 (1, N = 2002) = 7.3, p = 0.007, Figure 1d). However, the number of isolates per 
COVID+ and COVID− patients did not differ in any clinical area (Wilcoxon-Mann-Whit-
ney p > 0.05, Supplementary Figure S3). Conversely, the number of isolates per patient in 
the ICU was significantly higher than the number of isolates per patient in cardiology, the 
ER, medicine, and surgery (Supplementary Figure S3). Furthermore, the number of iso-
lates per patient in the ER was lower than the number of isolates per patient in medicine 
and surgery (Supplementary Figure S3). In addition, some significant differences were 
also observed among the number of isolates per patient when analyzing separately iso-
lates from COVID+ and COVID− patients. In fact, COVID− patients in the ER showed a 
lower number of isolates compared to those in the ICU, medicine, and surgery; COVID− 
patients in cardiology bore fewer strains compared to COVID− patients in the ICU, med-
icine, and surgery; COVID− patients in the ICU showed more isolates than those in med-
icine and surgery. Conversely, COVID+ patients in the ICU bore more strains compared 
to those in medicine and surgery (Supplementary Figure S3). Concerning the source of 
isolation of the strains, there were no specimens significantly more analyzed in COVID+ 
or in COVID− patients (Supplementary Figure S4). Together, these data suggest that ICU 
patients, either COVID+ or COVID−, have a higher chance of multi-strains infections and 
that multi-strain infections are more frequently detected in long-term clinical areas (the 
ICU, medicine, and surgery) than in the ER, with the latter more likely coping with com-
munity-acquired infections. 




Figure 1. Distribution of samples among patients having been tested positive (COVID+) or negative (COVID−) for COVID-
19 before collection of samples for microbial analysis. (a) Percentages and number of patients (and relative isolates) having 
been tested positive or negative for COVID-19 before collection of samples for microbial analysis. (b) Comparison of trends 
of new COVID-19 cases in Italy (red line, right vertical axis), bacterial strains isolated from COVID+ patients in our study 
cohort (black line, left vertical axis), and bacterial strains isolated from COVID− patients in our study cohort (grey line, 
left vertical axis). The time-periods of the first and second pandemic waves in Italy are reported over the plot. (c) Distri-
bution of patients and isolates among clinical areas. (d) Distribution of isolates from COVID+ and COVID− patients among 
clinical areas. 
3.2. Microbial Species Isolated from COVID+ and COVID− Patients 
We then focused on the distribution of bacterial species, first by comparing the num-
ber (measured as observed, Shannon, and Simpson alpha diversity indexes) of species 
isolated from samples grouped according to the year or month of isolation, COVID-19 
status (COVID+ or COVID−), clinical area, and source of isolation, then by assessing the 
presence of species isolated uniquely to either COVID+ or COVID− patients. The strains 
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under investigation belonged to a total of 100 species, distributed among 33 genera (Sup-
plementary Table S3). The most abundant species was Escherichia coli (420 isolates), fol-
lowed by Klebsiella pneumoniae (n = 192), Pseudomonas aeruginosa (n = 187), Enterococcus 
faecalis (n = 184), Staphylococcus epidermidis (n = 175), and Staphylococcus aureus (n = 134) 
(Supplementary Table S3). The remaining species were represented with less than 100 iso-
lates, and 42 species showed only one isolate each (Supplementary Table S3). According 
to every compared alpha diversity index, COVID+ patients bore a significantly higher 
number of bacterial species compared to COVID− (Figure 2a and Supplementary Figure 
S5a, Wilcoxon-Mann-Whitney p < 0.05). Similarly, a significantly lower number of species 
was isolated from patients hospitalized in the surgery area compared to the patients in 
the ER, ICU, and medicine and in cardiology compared to medicine and the ER (Supple-
mentary Figure S5b). Furthermore, bronchoaspiration, blood, catheter urine, and venous 
catheter were the specimens associated with the highest number of bacterial species (Sup-
plementary Figure S5c and Supplementary Table S4). Contrarily, we did not observe sig-
nificant differences among the alpha diversity indexes of bacterial sub-populations iso-
lated from the different patients nor from COVID+ or COVID− patients analyzed over the 
first or second waves of the pandemic in Italy. 
 
Figure 2. Distribution of bacterial species among patients. (a) Observed number of species per patient, grouped according 
to the COVID-19 status. Each point indicates a different group of strains (grouped as being isolated in the same month 
and year, from patients hospitalized in the same clinical area and being either COVID+ or COVID−). (b) Species whose 
abundance significantly differed among COVID+ and COVID− patients. (c) First two coordinates of the principal coordi-
nate analysis based on the Jaccard distances calculated among samples grouped as described for panel a. On the left part, 
the distribution of isolates, on the right part the distribution of the most abundant bacterial species. * = Wilcoxon-Mann-
Whitney p value < 0.05. 
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Among the 100 identified species, 8 were isolated only from COVID+ patients, 49 
were isolated only from COVID− patients, and the remaining 45 were present in both 
COVID+ and COVID− specimens (Supplementary Table S5). To note, most of the species 
isolated only from either COVID+ or COVID− patients can be considered accidental, as 
these species were represented by only one isolate (7 out of the 8 species isolated only 
from COVID+ patients and 33 out of the 49 species isolated only from COVID− patients, 
Supplementary Table S5). Conversely, the species isolated repeatedly only from either 
COVID+ or COVID− patients were: Corynebacterium spp. (3 isolates from COVID+ pa-
tients), Achromobacter spp. (n = 7, COVID−), Citrobacter youngae (n = 2, COVID−), Coryne-
bacterium matruchotii (n = 3, COVID−), Enterobacter asburiae (n = 2, COVID−), Hafnia alvei (n 
= 4, COVID−), Mycobacterium tuberculosis complex (n = 2, COVID−), Serratia liquefaciens 
(n = 2, COVID−), Staphylococcus coag. negative (n = 5, COVID−), Staphylococcus cohnii spp. 
urealyticum (n = 2, COVID−), Staphylococcus schleiferi (n = 2, COVID−), Staphylococcus xy-
losus (n = 2, COVID−), Streptococcus agalactiae Gr B (n = 3, COVID−), Streptococcus bovis II 
(n = 2, COVID−), Streptococcus dysgalactiae spp. equisimilis (n = 3, COVID−), Streptococcus 
oralis (n = 2, COVID−), Streptococcus pyogenes Gr A (n = 2, COVID−) (Supplementary Table 
S5). To note, whereas the species identified only among COVID− isolates are commonly 
considered as opportunistic pathogens capable of setting human infections, most of the 
species found only among COVID+ strains are known to establish infections only in im-
munocompromised patients (2 out of the 8 COVID+ specific species vs. 3 out of the 49 
COVID− specific species, Supplementary Table S5). Furthermore, two species were signif-
icantly more frequently isolated from either COVID+ or COVID− specimens: whereas Aci-
netobacter baumannii isolates were more abundant among COVID+ isolates than among 
COVID− isolates (1.89% of COVID+ isolates, 0.14% of COVID− strains), Escherichia coli was 
more frequently isolated from COVID− patients (23.84% and 13.97% of the strains isolated 
from COVID− and COVID+ patients, respectively) (Wilcoxon-Mann-Whitney p < 0.05, Fig-
ure 2b). 
Despite the presence of bacterial species characterizing COVID+ and COVID− pa-
tients, these characteristics were not sufficient to determine bacterial population profiles 
characterizing these two groups of patients. Indeed, as clearly depicted by the first two 
components of the principal coordinates analysis on Jaccard distances among groups of 
isolates (Figure 2c), the composition of bacterial populations was not statistically different 
between COVID+ and COVID− patients (permutational multivariate analysis of variance 
p = 0.131). Similarly, there was not a significant difference in the microbial composition of 
sub-populations isolated from the different patients nor from COVID+ or COVID− pa-
tients analyzed over the first or second waves of the pandemic in Italy. 
3.3. Antimicrobial Susceptibility of Bacterial Strains Isolated from COVID+ and  
COVID− Patients 
The susceptibility of bacterial isolates was assessed for a total of 18 antibiotics, with 
the set of antibiotics tested depending on the species of the isolate under investigation 
(Supplementary Table S2). The antibiotic that was tested against the largest number of 
isolates was ciprofloxacin (Cip, n = 1828), a fluoroquinolone with broad-spectrum bacte-
ricidal activity, followed by gentamicin (Gm, n = 1788) and trimethoprim/sulfamethoxa-
zole (Sxt, n = 1761). The antibiotic showing the highest percentage of resistant isolates 
(77.8%, n = 28) was ceftriaxone (Cro), whereas the antibiotics showing the lowest percent-
ages of resistant isolates were amikacin (An, 8.7%, n = 89), meropenem (Mem, 10.6%, n = 
37), imipenem (Ipm, 13.4%, n = 52), and piperacillin-tazobactam (Pta, 16.5%, n = 189) (Sup-
plementary Table S2). One hundred and sixty-six strains, corresponding to 8.3% of the 
isolates, were resistant to every tested antibiotic (Supplementary Table S6). Among these, 
72 were isolated from COVID+ patients (12% of the strains isolated from COVID+ pa-
tients) and 94 were isolated from COVID− patients (6.6% of the strains isolated from 
COVID− patients), indicating a correlation between the positivity to COVID-19 and the 
resistance to every tested antibiotic (Chi square test, Χ2 (1, N = 2002) = 18.2, p = 0.000019). 
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We found correlations between the percentage of strains isolated over the analyzed 
months from either COVID+ or COVID− patients and resistant to some antibiotics and the 
number of new COVID-19 cases at the national level in the same month (Supplementary 
Figure S6). In particular, we found that the number of new COVID-19 cases was nega-
tively correlated with the resistances to colistin (Cl) of both COVID+ and COVID− isolates, 
positively correlated with the resistances to norfloxacin (Nor), tetracycline (Te), and chlo-
ramphenicol (c) of both COVID+ and COVID− isolates, negatively correlated with the re-
sistance of COVID− isolates to cefepime (Fep), ceftazidime (Caz), ceftriaxone (Cro), and 
imipenem (Ipm), and positively correlated with the resistance of COVID− isolates to pip-
eracillin (Pip) (Supplementary Figure S6). To note, the single Corynebacterium renale, 
Corynebacterium jeikeium, Enterococcus avium, and Burkholderia cepacia, all the Corynebacte-
rium matruchotii (n = 3, all from COVID+ patients), and the vast majority of Enterococcus 
faecium (41 out of 52 total isolates, corresponding to the 78.8%) and Corynebacterium amy-
colatum (3 out of 4 total isolates) isolates were resistant to all the tested antibiotics (Sup-
plementary Tables S5 and S6). Although neither all COVID+ or COVID− isolates showed 
characteristic responses to the tested antibiotics (e.g., all the COVID+ isolates being re-
sistant to a given antibiotic, Figure 3a), significant differences were observed between the 
responses of COVID+ and COVID− isolates to some antibiotics (Figure 3b). In particular, 
strains isolated from COVID+ patients were significantly more resistant to amikacin (An), 
aztreonam (Azt), levofloxacin (Lvx), meropenem (Mem), and gentamicin (Gm) compared 
to COVID− isolates (Wilcoxon-Mann-Whitney p < 0.05, Figure 3b). Conversely, COVID− 
isolates were significantly more susceptible to cefepime (Fep), cefotaxime (Ctx), 
ceftazidime (Caz), imipenem (Ipm), piperacillin (Pip), and piperacillin-tazobactam (Pta) 
(Wilcoxon-Mann-Whitney p < 0.05, Figure 3b). 




Figure 3. Distribution of antimicrobial resistances among COVID+ and COVID− patients. (a) per-
centages of isolates Resistant (R), Intermediate (I), and Susceptible (S) to the indicated antibiotics. 
(b) Violin plots showing the responses to antibiotics significantly different between COVID+ and 
COVID− patients’ isolates (Wilcoxon-Mann-Whitney p < 0.05). “+/−” = ratio between the percentage 
of COVID+ and COVID− isolates showing the corresponding response to the antibiotic. An = ami-
kacin, Azt = aztreonam, Fep = cefepime, Ctx = cefotaxime, Caz = ceftazidime, Cro = ceftriaxone, Ipm 
= imipenem, Lvx = levofloxacin, Mem = meropenem, Nor = norfloxacin, Pip = piperacillin, Pta = 
piperacillin-tazobactam, Te = tetracycline, Sxt = trimethoprim/sulfamethoxazole, Gm = gentamicin, 
Cl = colistin, Cip = ciprofloxacin, c = chloramphenicol. 
3.4. Comparison of Bacterial Infections before and during the COVID-19 Pandemic 
Considering the suspected impact of COVID-19 treatments on AMR (antimicrobial 
resistance), we wondered if this hypothesized AMR increase could be (already) detected. 
Hence, by taking advantage of a dataset including information on bacterial strains isolated 
from the same Hospital prior to the onset of the pandemic (2018–2019) [28], we compared 
the species and relative antibiotic resistances of strains isolated from clinical patients be-
fore and during the COVID-19 pandemic from both COVID+ and COVID− patients. The 
dataset of the pre-pandemic survey encompassed 1583 bacterial isolates belonging to 89 
species distributed in 33 genera and 24 families. Whereas sixty-three species were largely 
represented in the dataset (with at least 5 isolates), 28 species (21 different genera) were 
represented by only one isolate. 
Whereas 61 bacterial species were consistently isolated both before and during the 
COVID-19 pandemic (without differences in the frequency of isolation, Supplementary 
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Table S7), 28 species were isolated only before the advent of the COVID-19 pandemic 
(Supplementary Table S7). However, it has to be noted that for only 11 species out of these 
28 more than one strain had been isolated before COVID-19: Bacteroides fragilis (n = 2), 
Klebsiella pneumoniae spp. ozaenae (n = 3), Listeria monocytogenes (n = 4), Shigella dysenteriae 
(n = 2), Staphylococcus caprae (n = 4), Staphylococcus gallinarum (n = 2), Streptococcus dysga-
lactiae (Gr C) (n = 2), Staphylococcus saprophyticus (n = 5), Streptococcus gr C (n = 2), Strepto-
coccus salivarius (n = 2), Streptococcus sobrinus (n = 2). On the other hand, 38 species were 
isolated only since the beginning of the COVID-19 pandemic (Supplementary Table S7). 
Even in this case, only one strain, mostly from COVID+ patients, was isolated for several 
(29) of these species (Supplementary Table S7). Conversely, several strains were isolated 
for the species Enterobacter asburiae, Serratia plymuthica, Staphylococcus cohnii spp. urealyti-
cum (n = 2), Staphylococcus sciuri, Staphylococcus simulans, Streptococcus dysgalactiae spp. eq-
uisimilis (n = 3), Staphylococcus lugdunensis and Citrobacter farmeri (respectively n = 7 and n 
= 6) (Supplementary Table S7). 
Overall, the response of isolates to the tested antibiotics did not change between be-
fore and during the COVID-19 pandemic (Figure 4, Chi-square test p > 0.05). The same 
situation was observed when comparing the susceptibilities to the tested antibiotic be-
tween co-specific strains isolated before and during the pandemic (Chi-square test p > 
0.05), indicating that either the pandemic has not promoted the insurgence of antibiotic 
resistance or that the increase is not yet observable. 
 
Figure 4. Percentages of strains, isolated during (left) and before (right) the COVID-19 pandemic, resistant to the tested 
antibiotics. An = amikacin, Azt = aztreonam, Fep = cefepime, Ctx = cefotaxime, Caz = ceftazidime, Cro = ceftriaxone, Ipm 
= imipenem, Lvx = levofloxacin, Mem = meropenem, Nor = norfloxacin, Pip = piperacillin, Pta = piperacillin-tazobactam, 
Te = tetracycline, Sxt = trimethoprim/sulfamethoxazole, Gm = gentamicin, Cl = colistin, Cip = ciprofloxacin, c = chloram-
phenicol. The test aimed at evaluating susceptibility to norfloxacin was introduced after gathering data relative to “before 
COVID-19 pandemic”. 
4. Discussion 
Our dataset of bacterial strains isolated from clinical samples over one year from the 
onset of the COVID-19 pandemic provided a balanced representation of bacterial infec-
tions occurring at various body sites and in various clinical areas, both in COVID+ and 
COVID− patients. In fact, we did not observe any significant difference between COVID+ 
and COVID− isolates in the distribution of isolates among clinical areas or isolation 
sources. Conversely, we could observe that multiple strains from different species are 
more frequently isolated from COVID+ patients than from COVID− patients, also corrob-
orated by a significantly higher number of species associated with COVID+ patients than 
with COVID− patients. This observation may be ascribed to the systemic frailty of patients 
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suffering from the viral infection or to the prolonged utilization of invasive life support 
machines, which may promote the onset of microbial infections [29]. It is not possible to 
determine which of the two hypotheses prevails because multiple strains were more fre-
quently isolated from specimens sampled from hospitalized patients than from ER pa-
tients, hence suggesting that single-strain infections are usually community-acquired and 
multiple-strains infection are more likely to be acquired over prolonged hospitalization 
periods, with the latter being commonly subjected to the use of ventilators or other inva-
sive procedures and often suffering from pathologies resulting in a general debility. An 
alternative cause of the observation of multiple strains isolated from non-ER patients 
could be ascribed to the fact that, whereas ER patients were sampled only once, samples 
from non-ER clinical areas were mostly collected on multiple occasions (over the period 
of hospitalization of the patient). In fact, we found that the number of isolates per patient 
in the ER was significantly lower than the number of isolates per patient in medicine and 
surgery. However, the fact that multiple strains were isolated from COVID+ patients can-
not be entirely ascribed to the repeated sampling of these patients over ER-patients be-
cause we did not observe a significant difference between COVID+ and COVID− patients 
in the ER. It has to be considered that, despite the identification of bacterial strains as 
potentially causative of the infection is carried out by taking into consideration the entire 
clinical profile and symptoms of the patient, some of the isolates included in our dataset, 
especially those found in co-occurrence with other strains, may be commensal, rather than 
the pathogens responsible for the infection. However, considering that the main aim of 
this study was to assess the impact of the COVID-19 pandemic on the spread of antimi-
crobial resistance, the results should not be affected by the inclusion of commensal strains. 
To note, the number of bacterial isolates from COVID+ patients was correlated with 
the number of new COVID-19 cases monitored at the national level, suggesting a high 
chance of bacterial infection co-occurrence. In correspondence with the peak in the num-
ber of new COVID-19 cases the government imposed general lockdown measures (limit-
ing socialization) and hospitalization for planned and delayable procedures was post-
poned to redirect the activity of sanitary workers toward the cure and care of COVID-19 
patients (thus reducing the chances of occurrence of nosocomial infections). Hence, we 
expected to find a negative correlation between the number of bacterial isolates from 
COVID− patients and the number of new cases. Conversely, this hypothesis was not sta-
tistically supported, possibly indicating that the limitations imposed for the sanitary 
emergency did contain the spread of the virus, but not the insurgence of bacterial infec-
tions. The observation of the correlation between the number of bacterial isolates and the 
number of new COVID-19 cases at the national level can be an indication of the fact that 
all the COVID-19 patients have the same chance of acquiring a bacterial infection, (hence 
if the number of COVID-19 cases increases then also the number of bacterial isolates does) 
and that the number of new COVID-19 patients hospitalized at the hospital under inves-
tigation in this study has the same trend as the number of new COVID-19 cases at the 
national level. Whereas we could not evaluate the validity of the first point, as it can be 
evaluated only through a multi-center survey; however, we did confirm the latter through 
the observation of a positive correlation between the number of new COVID-19 cases at 
the national and provincial (Turin) levels (Pearson correlation r = 0.677 p < 2.2*10^-16, 
Supplementary Figure S7). 
Not surprisingly, considering the overall debilitation of COVID+ patients, a large 
part of the species identified only among the isolates from COVID+ patients are com-
monly associated with infections in immuno-compromised patients (Burkholderia cepacia 
and Citrobacter braakii) or nosocomial infections (Sphingomonas paucimobilis) [30–32]. To 
note, the observation that Klebsiella pneumoniae was isolated more frequently from 
COVID+ patients than from COVID− patients, possibly associated with the use of invasive 
devices widely used in the treatment of COVID-19 (ventilator and urinary catheters), may 
support the current dread of increase of nosocomial infections and AMR as an indirect 
consequence of the COVID-19 pandemic. In fact, this species is among the most dreadful 
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current causes of healthcare-associated infections including pneumonia, urinary tract in-
fections, and bloodstream infections and is also frequently associated with multi-drug re-
sistance [33]. On the other hand, the observation of Acinetobacter baumannii/haemolyticus 
being more abundant among the COVID+ isolates than among the COVID− ones is not 
surprising, as this species is known to cause ventilator-associated and bloodstream infec-
tions in critically ill patients [34], both conditions obviously present in COVID+ patients. 
Conversely, Escherichia coli, one of the most frequent causes of common bacterial infec-
tions in humans [35] and the most frequently isolated species in our dataset, was also more 
frequently isolated from COVID− than from COVID+ patients. Furthermore, the fact that 
E. coli was the species most likely represented among the urine isolates in COVID− pa-
tients, as commonly occurring in urinary tract infections [36] and not in COVID+ patients 
suggests that in the presence of SARS-CoV-2 infections, this opportunistic pathogen can 
equally infect various body sites. 
Our dataset seems to support the predicted impact of the COVID-19 on the spread of 
AMR infections: the fraction of microorganisms resistant to every tested antibiotic is 
higher in COVID+ than in COVID− isolates. Furthermore, COVID+ isolates show higher 
resistance to amikacin and gentamicin (aminoglycosides), aztreonam (monobactam), 
levofloxacin (third-generation fluoroquinolone), meropenem (beta-lactam). All the above-
mentioned antibiotics are used as the first line therapeutic agents for the management of 
severe pneumonia, and the diffusion of resistance toward them limits their efficacy. More-
over, the possibility of exploiting the antiviral activity of these antibiotics against SARS-
CoV-2 was evaluated, but the ability of fluoroquinolones (such as levofloxacin) to sup-
press SARS-CoV-2 and MERS-CoV replication in cultured cells has been proven limited 
[11], the effectiveness of aminoglycosides (such as gentamicin and amikacin) against 
SARS-CoV-2 due to production of retrocyclins [9], and the binding of meropenem to 
SARS-CoV-2 protease [10] still need to be demonstrated. Hence, it is reasonable to assume 
that the antibiotics toward which COVID+ isolates showed a high resistance had been 
administered as part of the therapy, thus promoting the selection of resistant strains. To 
further confirm these findings, future investigations will have to consider clinical and de-
mographic characteristics of the patients infected by bacteria, hence assessing the impact 
of variables such as age, gender, presence of comorbidities, and clinical treatments on the 
insurgence of bacterial infection and, eventually, on the occurrence of antibacterial re-
sistance. 
It is worth noting that neither COVID+ nor COVID− isolates showed significantly 
higher resistance to trimethoprim/sulfamethoxazole, indicated among the drugs to be ad-
ministered to COVID+ patients, nor to ceftriaxone, a cephalosporin indicated for COVID-
19 infection domestic treatment in the presence of a reasonable suspicion of concomitant 
bacterial or viral infection over the early phases of the pandemic [12]. However, our study 
lacks the population of COVID+ patients who have not been hospitalized, due to govern-
ment regulations recommending limiting access to hospitals and treating patients at home 
whenever possible. In this regard, therefore, we cannot exclude that the lack of observa-
tion of resistance to antibiotics used mainly outside the hospital is due to the fact that we 
have not analyzed the population exposed to those antibiotics. It is also worth noting that 
the significantly higher susceptibility of COVID− isolates to cefepime, cefotaxime, 
ceftazidime, imipenem, piperacillin, and piperacillin-tazobactam may indicate that 
COVID+ isolates show more frequently an intermediate response or are resistant to these 
antibiotics, suggesting a trend toward the increase of AMR against them. Even more wor-
ryingly, more COVID+ isolates than COVID− isolates were resistant to every tested anti-
biotic, further suggesting that the COVID-19 infection has an impact on the insurgence or 
selection of multi-resistant strains. This observation seems to be particularly relevant for 
the Burkholderia cepacia, Corynebacterium renale, Corynebacterium jeikeium, Corynebacterium. 
matruchotii, Corynebacterium amycolatum, Enterococcus avium, and Enterococcus faecium spe-
cies, whose strains isolated from COVID+ patients showed high levels of multiple antibi-
otic resistance. However, the comparison of strains isolated before and over the course of 
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the COVID-19 pandemic provided a different and hence slightly reassuring portrait: the 
level of antibiotic resistance against the tested antibiotic is not significantly different 
among the two sets. Hence overall, the delayed treatments, and the diagnostic and surgi-
cal errors observed over the pandemic [37] have not obviously (or yet) impacted on the 
spread of bacterial infection and on the insurgence of resistances. Nevertheless, this ob-
servation has to be taken with caution. In fact, an increase in antibiotic resistance may be 
occurring, but it may not be perceivable yet. 
Supporting the hypothesis that a change in microbial infections is occurring in asso-
ciation with the COVID-19 pandemic is the observation of differences between the micro-
bial species identified before and during the pandemic. The fact that some species were 
isolated only before or over the COVID-19 pandemic may be ascribed to different social 
behaviors over the pandemic or, in the case of species more frequently isolated from 
COVID+ patients, to the COVID-19 infection per se (or to the adopted therapy). It is inter-
esting to observe that, despite the analytical procedure for the identification of Staphylo-
coccus lugdunensis has been recently improved, such an improvement was achieved before 
the acquisition of the dataset relative to strains isolated before the COVID-19 pandemic 
[38]. Hence, the lack of observation of this species before the pandemic must not be as-
cribed to the incapability of identifying this species. 
5. Conclusions 
The key points emerging from our study are highlighted hereafter: 
1. No significant differences were observed between COVID+ and COVID− in the 
distribution of isolates among clinical areas or isolation sources; 
2. Conversely, multiple strains from different species are more frequently isolated from 
COVID+ patients than from COVID− patients, and a significantly higher number of 
species was associated with COVID+ patients than with COVID− patients; 
3. The number of bacterial isolates from COVID+ patients was correlated with the 
number of new COVID-19 cases monitored at the national level; 
4. Several species identified only among COVID+ patients are commonly associated 
with infections in immuno-compromised patients or nosocomial infections. Klebsiella 
pneumoniae and Acinetobacter baumannii/haemolyticus were more abundant among 
COVID+ isolates; 
5. The fraction of microorganisms resistant to every tested antibiotic is higher in 
COVID+ than in COVID− isolates. Furthermore, COVID+ isolates show higher 
resistance to several antibiotics used as the first line therapeutic agents for the 
management of severe pneumonia; 
6. Resistance to trimethoprim/sulfamethoxazole was equally distributed between 
COVID+ and COVID− isolates; 
7. More COVID+ than COVID− isolates were resistant to every tested antibiotic. 
The COVID-19 pandemic has widely impacted not only the common habits of us all 
but also the profile of microbial infections and antimicrobial resistance. The changes in 
our social behaviors may have contributed to differentiating the species associated with 
infections before and during the current pandemic, but the predicted AMR, as a conse-
quence of the administration of broad-spectrum antibiotics to COVID+ patients is not ob-
servable yet. However, the higher frequency, among COVID+ isolates, of strains resistant 
to every tested antibiotic seems to indicate that the AMR increase is actually occurring, 
hence further calling for the definition of alternative treatments of COVID-19 infections, 
eventually encompassing antibiotics accurately selected if necessary and upon evaluation 
of the pathogen’s antibiogram. 
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